Published in J Glaucoma on August 01, 2002
Comparison of visual field defects using matrix perimetry and standard achromatic perimetry. Ophthalmology (2006) 1.77
Characteristics of the normative database for the Humphrey matrix perimeter. Invest Ophthalmol Vis Sci (2005) 1.19
Measurement error of visual field tests in glaucoma. Br J Ophthalmol (2003) 0.88
Relationship between visual field loss and contrast threshold elevation in glaucoma. BMC Ophthalmol (2005) 0.82
Standard automated perimetry versus matrix frequency doubling technology perimetry in subjects with ocular hypertension and healthy control subjects. PLoS One (2013) 0.77
Assessing the GOANNA Visual Field Algorithm Using Artificial Scotoma Generation on Human Observers. Transl Vis Sci Technol (2016) 0.75
[Frequency-doubling technology : A new method for determining glaucomatous visual field defects]. Ophthalmologe (2009) 0.75
The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol (2002) 16.89
The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol (2002) 11.38
A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol (2003) 9.99
Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthalmol (2010) 2.78
Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch Ophthalmol (2010) 2.14
Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Arch Ophthalmol (2004) 1.80
Classification of visual field abnormalities in the ocular hypertension treatment study. Arch Ophthalmol (2003) 1.76
Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol (2004) 1.71
Evaluation of the structure-function relationship in glaucoma. Invest Ophthalmol Vis Sci (2005) 1.64
Quantitation of cardiolipin molecular species in spontaneously hypertensive heart failure rats using electrospray ionization mass spectrometry. J Lipid Res (2005) 1.61
Pulsar perimetry in the diagnosis of early glaucoma. Am J Ophthalmol (2009) 1.57
The Nature of Macular Damage in Glaucoma as Revealed by Averaging Optical Coherence Tomography Data. Transl Vis Sci Technol (2012) 1.55
Normative ranges and specificity of the multifocal VEP. Doc Ophthalmol (2004) 1.52
Comparison of different methods for detecting glaucomatous visual field progression. Invest Ophthalmol Vis Sci (2003) 1.46
Frequency-doubling technology perimetry. Ophthalmol Clin North Am (2003) 1.34
Identification of progressive glaucomatous visual field loss. Surv Ophthalmol (2002) 1.33
Properties of perimetric threshold estimates from full threshold, ZEST, and SITA-like strategies, as determined by computer simulation. Invest Ophthalmol Vis Sci (2003) 1.30
How useful is population data for informing visual field progression rate estimation? Invest Ophthalmol Vis Sci (2013) 1.29
Psychophysical investigation of ganglion cell loss in early glaucoma. J Glaucoma (2005) 1.29
Development of efficient threshold strategies for frequency doubling technology perimetry using computer simulation. Invest Ophthalmol Vis Sci (2002) 1.27
Selective loss of an oscillatory component from temporal retinal multifocal ERG responses in glaucoma. Invest Ophthalmol Vis Sci (2002) 1.26
Comparing multifocal VEP and standard automated perimetry in high-risk ocular hypertension and early glaucoma. Invest Ophthalmol Vis Sci (2007) 1.24
Determining abnormal latencies of multifocal visual evoked potentials: a monocular analysis. Doc Ophthalmol (2004) 1.23
Using machine learning classifiers to identify glaucomatous change earlier in standard visual fields. Invest Ophthalmol Vis Sci (2002) 1.23
Staging functional damage in glaucoma: review of different classification methods. Surv Ophthalmol (2007) 1.20
Characteristics of the normative database for the Humphrey matrix perimeter. Invest Ophthalmol Vis Sci (2005) 1.19
Flavin-dependent antioxidant properties of a new series of meso-N,N'-dialkyl-imidazolium substituted manganese(III) porphyrins. Biochem Pharmacol (2004) 1.19
Community visual field screening: prevalence of follow-up and factors associated with follow-up of participants with abnormal frequency doubling perimetry technology results. Ophthalmic Epidemiol (2007) 1.18
Longitudinal and cross-sectional analyses of visual field progression in participants of the Ocular Hypertension Treatment Study. Arch Ophthalmol (2010) 1.18
The association between glaucomatous visual fields and optic nerve head features in the Ocular Hypertension Treatment Study. Ophthalmology (2006) 1.16
Comparison of the new perimetric GATE strategy with conventional full-threshold and SITA standard strategies. Invest Ophthalmol Vis Sci (2008) 1.16
Performance of efficient test procedures for frequency-doubling technology perimetry in normal and glaucomatous eyes. Invest Ophthalmol Vis Sci (2002) 1.14
Effect of dichoptic adaptation on frequency-doubling perimetry. Optom Vis Sci (2002) 1.14
Comparison of glaucomatous visual field defects using standard full threshold and Swedish interactive threshold algorithms. Arch Ophthalmol (2002) 1.12
Frequency-doubling technology perimetry and optical defocus. Invest Ophthalmol Vis Sci (2003) 1.11
Progression of visual field loss in untreated glaucoma patients and glaucoma suspects in St. Lucia, West Indies. Am J Ophthalmol (2002) 1.10
The methodology of visual field testing with frequency doubling technology in the National Health and Nutrition Examination Survey, 2005-2006. Ophthalmic Epidemiol (2010) 1.09
Size threshold perimetry performs as well as conventional automated perimetry with stimulus sizes III, V, and VI for glaucomatous loss. Invest Ophthalmol Vis Sci (2013) 1.09
The repeatability of mean defect with size III and size V standard automated perimetry. Invest Ophthalmol Vis Sci (2013) 1.06
Determining abnormal interocular latencies of multifocal visual evoked potentials. Doc Ophthalmol (2004) 1.05
Glaucomatous progression in series of stereoscopic photographs and Heidelberg retina tomograph images. Arch Ophthalmol (2010) 1.04
Factors predicting the rate of functional progression in early and suspected glaucoma. Invest Ophthalmol Vis Sci (2012) 1.04
Perimetric indices as predictors of future glaucomatous functional change. Optom Vis Sci (2011) 1.04
Causes of visual impairment and common eye problems in Northwest American Indians and Alaska Natives. Am J Public Health (2005) 1.03
Mechanisms isolated by frequency-doubling technology perimetry. Invest Ophthalmol Vis Sci (2002) 1.03
Visual field profile of optic neuritis: a final follow-up report from the optic neuritis treatment trial from baseline through 15 years. Arch Ophthalmol (2010) 1.01
Decline of photopic multifocal electroretinogram responses with age is due primarily to preretinal optical factors. J Opt Soc Am A Opt Image Sci Vis (2002) 1.01
Sensitivity and specificity of the Swedish interactive threshold algorithm for glaucomatous visual field defects. Ophthalmology (2002) 1.00
Is there evidence for continued learning over multiple years in perimetry? Optom Vis Sci (2008) 0.98
Visual field quality control in the Ocular Hypertension Treatment Study (OHTS). J Glaucoma (2007) 0.97
Use of a continuous probability scale to display visual field damage. Arch Ophthalmol (2009) 0.95
Normal visual field test results following glaucomatous visual field end points in the Ocular Hypertension Treatment Study. Arch Ophthalmol (2005) 0.95
Variability of rarebit and standard perimetry sizes I and III in normals. Optom Vis Sci (2011) 0.94
Repeatability of normal multifocal VEP: implications for detecting progression. J Glaucoma (2006) 0.93
Normal age-related sensitivity loss for a variety of visual functions throughout the visual field. Optom Vis Sci (2006) 0.93
Asymmetries and visual field summaries as predictors of glaucoma in the ocular hypertension treatment study. Invest Ophthalmol Vis Sci (2006) 0.93
Imaging and Perimetry Society standards and guidelines. Optom Vis Sci (2011) 0.92
Predictive value of frequency doubling technology perimetry for detecting glaucoma in a developing country. J Glaucoma (2005) 0.92
The effect of test variability on the structure-function relationship in early glaucoma. Graefes Arch Clin Exp Ophthalmol (2012) 0.91
Predicting progressive glaucomatous optic neuropathy using baseline standard automated perimetry data. Invest Ophthalmol Vis Sci (2008) 0.89
Sensitivity differences between real-patient and computer-stimulated visual fields. J Glaucoma (2002) 0.88
Estimating quality-adjusted life year losses associated with visual field deficits using methodological approaches. Ophthalmic Epidemiol (2007) 0.88
Elevated vernier acuity thresholds in glaucoma. Invest Ophthalmol Vis Sci (2002) 0.88
Assessment of linear-scale indices for perimetry in terms of progression in early glaucoma. Vision Res (2011) 0.87
Assessment of false positives with the Humphrey Field Analyzer II perimeter with the SITA Algorithm. Invest Ophthalmol Vis Sci (2006) 0.87
Scotoma mapping by semi-automated kinetic perimetry: the effects of stimulus properties and the speed of subjects' responses. Acta Ophthalmol Scand (2006) 0.87
Sensitivity and specificity of the Humphrey Matrix to detect homonymous hemianopias. Invest Ophthalmol Vis Sci (2008) 0.87
The 5-lipoxygenase pathway is required for acute lung injury following hemorrhagic shock. Shock (2012) 0.86
Perceived spatial frequency of sinusoidal gratings. Optom Vis Sci (2008) 0.85
Refinement of pointwise linear regression criteria for determining glaucoma progression. Invest Ophthalmol Vis Sci (2013) 0.84
Morphometric analysis and classification of glaucomatous optic neuropathy using radial polynomials. J Glaucoma (2012) 0.84
Humphrey Matrix perimetry in optic nerve and chiasmal disorders: comparison with Humphrey SITA standard 24-2. Invest Ophthalmol Vis Sci (2008) 0.84
Frequency doubling technology perimetry in normal children. Am J Ophthalmol (2006) 0.84
Factors Affecting Visual Field Outcomes in the Idiopathic Intracranial Hypertension Treatment Trial. J Neuroophthalmol (2016) 0.83
Features of optic disc progression in patients with ocular hypertension and early glaucoma. J Glaucoma (2013) 0.83
Anatomy of a supergroup: does a criterion of normal perimetric performance generate a supernormal population? Invest Ophthalmol Vis Sci (2003) 0.82
Comparison of the ASA, MOBS, and ZEST threshold methods. Vision Res (2006) 0.82
Spatial and temporal processing of threshold data for detection of progressive glaucomatous visual field loss. Arch Ophthalmol (2002) 0.82
Total deviation probability plots for stimulus size v perimetry: a comparison with size III stimuli. Arch Ophthalmol (2008) 0.82
Mammalian fatty acid synthase activity from crude tissue lysates tracing ¹³C-labeled substrates using gas chromatography-mass spectrometry. Anal Biochem (2012) 0.81
Cup size predicts subsequent functional change in early glaucoma. Optom Vis Sci (2011) 0.81
The results of screening frequency doubling technology perimetry in different locations of the community. J Glaucoma (2007) 0.81
Learning effect and test-retest variability of pulsar perimetry. J Glaucoma (2013) 0.80
Normative Databases for Imaging Instrumentation. J Glaucoma (2015) 0.80
Measuring visual function in age-related macular degeneration with frequency-doubling (matrix) perimetry. Optom Vis Sci (2011) 0.80
Evaluation of decision rules for frequency-doubling technology screening tests. Optom Vis Sci (2006) 0.79
Short-wavelength sensitivity deficits in patients with migraine. Arch Ophthalmol (2002) 0.78
Appearance of the frequency doubling stimulus in normal subjects and patients with glaucoma. Invest Ophthalmol Vis Sci (2003) 0.78
Effect of recording duration on the diagnostic performance of multifocal visual-evoked potentials in high-risk ocular hypertension and early glaucoma. J Glaucoma (2008) 0.77
Visual field defects. Seizure (2002) 0.75
Author response: effect of intraocular pressure on the Bayesian estimation of rates of visual field progression in glaucoma. Invest Ophthalmol Vis Sci (2013) 0.75
Are high-pass resolution perimetry thresholds sampling limited or optically limited? Optom Vis Sci (2002) 0.75
A comparison of catch trial methods used in standard automated perimetry in glaucoma patients. J Glaucoma (2008) 0.75
Glaucoma: recent discoveries and patient care. Optom Vis Sci (2011) 0.75
Effect of spatial waveform on apparent spatial frequency. Vision Res (2002) 0.75